The Efficacy of Marketed Injectable Insulins Is Difficult To Improve Upon and This Is Reflected In the R&D Pipeline for Insulins.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c42625) has announced the addition of Pipeline Insight: Insulins - Inhalable Insulins Unlikely to Become Blockbusters to their offering

The author expects the continuously growing prevalence of diabetes to drive growth in diabetes drug spending, potentially benefiting market uptake of novel insulin therapies. A set of novel, non-injectable insulins are poised to become available to patients in the next five years. By 2010, the market will thus have to absorb Pfizers Exubera and at least three other inhalable insulins.

Scope of this title:

* Assessment of the patient potential for developmental insulin therapy over the period 2006 to 2015

* Overview of the insulin pipeline, with detailed information on the insulins in development and injectable comparators as well as market entry barriers

* Commercial analysis of key insulin products in development regarding their ability to satisfy unmet needs, supported by the views of opinion leaders

* Sales forecasts for four key inhalable insulin preparations in the seven major markets to 2015

Highlights of this title:

* The diabetes market is worthy of investment because of the endemic size of its patient pool which is set to grow further. However, the efficacy of marketed injectable insulins is difficult to improve upon and this is reflected in the R&D pipeline for insulins, comprising a small set of only 17 novel insulin products in clinical development.

* The research has identified three late-stage insulins likely to be launched into the diabetes market within the next five years. These are the inhalable formulations AERx-iDMS, AIR and Technosphere all of which may coexist with Exubera because their technical diversity is likely to cater for a wide spectrum of patient needs and preference.

* The diabetes market will not be receptive to inhalable insulins until compelling data is generated that demonstrate compelling clinical benefits of inhalable insulins over injectables. This view is supported by the recent cost-benefit analyses of it by Germanys IQWiG and UKs NICE, and the distinct lack of opinion leader enthusiasm about Exubera.

Reasons to order your copy:

* Explore the key factors that will contribute to the success of the next generation of insulins.

* View independent sales forecasts for products in late stage development for insulin-based diabetes therapy

* Understand physician opinions of non-injectable insulins and unmet needs in the diabetes market

Chapter Titles are as Follows:

Chapter 1

Executive summary

Chapter 2

Pipeline overview

Chapter 3

Patient potential

Chapter 4

R&D approach

Chapter 5

Late-stage drug analysis & forecasts: insulins

Chapter 6

Other insulins

APPENDIX A

APPENDIX B

List of Tables

List of Figures

The Products Mentioned inside this report include:

* AERx-iDMS (Novo Nordisk)

* AIR insulin (Alkermes, Eli Lilly)

* Technosphere insulin (MannKind)

* Alveair (inhalable insulin)

* AT-1391

* DTY001 (Capsulin)

* Eligen oral insulin (Emisphere)

* Intesulin (oral insulin, Coremed)

* Intranasal Insulin (Bentley, Dong Sung, Biocon)

* KI-02212 (inhalable insulin, Kos)

* NBI-6024

* NN-344

* NN-5401

* Oral-lyn (Generex)

* QDose (inhalable insulin, QDose)

* Viaject

For more information visit http://www.researchandmarkets.com/reports/c42625

Source: Datamonitor